Johnson & Johnson vs Pfizer Inc.

Full side-by-side comparison — 2026

Updated automatically

JNJ

Price USD 272.67
P/E Ratio 41.5x
Div Yield 1.95%
Beta 0.20
Sector Health Care

PFE

Price USD 27.43
P/E Ratio 39.1x
Div Yield 6.28%
Beta 0.30
Sector Health Care

Price Overview

Metric JNJ PFE
Current Price 272.67 27.43
Previous Close 267.14 27.54

Valuation

Metric JNJ PFE
Trailing P/E 41.48 39.14
Forward P/E 23.55 9.28
Price / Book 8.07 1.75
Price / Sales 6.62 2.45
EV / EBITDA 20.24 8.24

Dividends & Income

Metric JNJ PFE
Dividend Yield 1.95% 6.28%
Dividend Rate (Annual) 5.28 1.72
5-Year Avg Yield 2.77% 4.48%
Payout Ratio 79.01% 242.80%

Risk & Financial Health

Metric JNJ PFE
Beta (Volatility) 0.20 0.30
Debt / Equity 54.77 71.01
Quick Ratio 0.65 1.00
Current Ratio 1.02 1.42

Growth & Profitability

Metric JNJ PFE
Revenue Growth 5.90% -0.40%
Earnings Growth -95.90% -9.70%
Return on Equity 20.02% 4.47%
Revenue / Share 41.25 11.17
Trailing EPS 6.59 0.70
Forward EPS 11.61 2.95

Analyst Targets

Metric JNJ PFE
Analyst Mean Target 280.18 30.22
Analyst High Target 320.00 37.00
Analyst Low Target 190.00 25.00

Bottom Line: JNJ vs PFE

Pfizer Inc. (PFE) leads on 10 of 15 comparable metrics.

Johnson & Johnson has a higher Revenue Growth (5.90% vs -0.40%), which indicates the business is expanding faster
Pfizer Inc. has a higher Earnings Growth (-9.70% vs -95.90%), which indicates profits are growing more quickly
Pfizer Inc. has a lower Price / Book (1.75 vs 8.07), which may indicate the stock trades closer to its book value

This comparison is based on publicly available financial data and is for informational purposes only. It is not investment advice. Past performance does not guarantee future results.

JNJ Johnson & Johnson

Best for Growth Investors
• Higher Revenue Growth: 5.90%
• Higher Return on Equity: 20.02%

PFE Pfizer Inc.

Best for Value Investors
• Lower Trailing P/E: 39.14
• Lower Forward P/E: 9.28
• Lower Price / Book: 1.75
Best for Income Investors
• Higher Dividend Yield: 6.28%
• Higher 5-Year Avg Yield: 4.48%

Watch Out

PFE's 6.28% yield looks attractive, but its 242.80% payout ratio signals the dividend may not be sustainable.

JNJ's earnings declined 96% — declining profits may mean current valuation metrics (PE, payout ratio) are misleading.

Analyst Upside / Downside

JNJ
+2.8%
PFE
+10.2%

Based on analyst mean price targets. Estimates are not guaranteed and may not reflect future performance.

About These Companies

Johnson & Johnson (JNJ)

Health Care · United States · NYQ

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in …

View JNJ details →

Pfizer Inc. (PFE)

Health Care · United States · NYQ

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, …

View PFE details →

Frequently Asked Questions

Which has a better dividend yield, JNJ or PFE?
Pfizer Inc. currently has the higher dividend yield. Johnson & Johnson (JNJ) yields 1.95% while Pfizer Inc. (PFE) yields 6.28%. Past dividends do not guarantee future payments.
Which is more volatile, JNJ or PFE?
Pfizer Inc. is more volatile based on beta. Johnson & Johnson has a beta of 0.20 and Pfizer Inc. has a beta of 0.30. A beta above 1.0 means higher volatility than the overall market.
Which is cheaper by P/E ratio, JNJ or PFE?
Pfizer Inc. has the lower trailing P/E ratio. Johnson & Johnson trades at 41.5x earnings while Pfizer Inc. trades at 39.1x. A lower P/E may suggest better relative value, but could also reflect lower growth expectations.
Which has more analyst upside, JNJ or PFE?
Based on mean analyst price targets, Pfizer Inc. has more upside potential. Johnson & Johnson has +2.8% upside and Pfizer Inc. has +10.2% upside from current prices. Analyst estimates are not guaranteed.
Can I track both JNJ and PFE in one portfolio?
Yes. AllInvestView lets you add both Johnson & Johnson and Pfizer Inc. to the same portfolio and monitor price changes, dividends, total return, and allocation — completely free.

Track JNJ and PFE in Your Portfolio

Add both to AllInvestView and compare their real-time performance, dividends, and gain/loss side by side.

Start Free Portfolio